Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease

Pharmacoeconomics. 2022 Aug;40(8):835. doi: 10.1007/s40273-022-01171-5.

Authors

Katya Galactionova¹, Paola Salari¹, Renato Mattli², Yael Rachamin^{3

4}, Rahel Meier^{3

4}, Matthias Schwenkglenks⁵

Affiliations

¹ Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.
² Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
³ Institute of Primary Care, University of Zurich, Zurich, Switzerland.
⁴ University Hospital Zurich, Zurich, Switzerland.
⁵ Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland. m.schwenkglenks@unibas.ch.

No abstract available

Publication types

Published Erratum